MA-SECURE-CODE-WARRIOR
24.3.2021 03:25:11 CET | Business Wire | Press release
New research from Secure Code Warrior ® , the global secure coding company, has revealed an attitudinal shift in the software development industry, with organisations bucking traditional practices for DevOps and Secure DevOps.
The global survey of professional developers and their managers found seven in 10 organisations (70%) recognise the importance of secure coding practices, with results indicating an industry-wide shift from reaction to prevention is underway.
Dr. Matias Madou, Chief Technology Officer and Co-Founder at Secure Code Warrior, said, “We are seeing a fundamental shift in mindsets across the world, as the industry slowly moves from reactive, band-aid solutions rolled out after a breach, to the proactive and human-led practice of writing quality software that is intrinsically free from vulnerabilities right from the very first keystroke. ”
“This research shows that ‘secure code’ is becoming synonymous with ‘quality code’ within software development, and security is becoming the responsibility of development teams and leaders—not just AppSec professionals, ” he said.
Secure coding seen as ‘reactive’
Reactive practices like using tools on deployed applications and manually reviewing code for vulnerabilities were the top two practices respondents associated with coding securely. However, a proactive shift in mindset was evidenced across the globe, with more than half (55%) of the developers surveyed also recognising secure coding as the active, ongoing practice of writing software protected from vulnerabilities.
Managers and developers are misaligned
Over half (55%) of managers surveyed said secure coding was practised and integrated throughout the entire development process, compared to only 43% of developers. Conversely, 36% of developers consider secure coding during development but not the design phase, as opposed to under one-third (32%) of managers.
Secure code an increasing indicator of success
While those surveyed identified ‘application performance’ and ‘functionality and features’ as the most common success metrics within software development (67% and 62% respectively), almost four in five (79%) respondents said the importance of ‘secure code’ was growing in prominence.
Application security is shifting
Almost half of respondents (46%) said development leads and teams should be responsible for application security rather than AppSec teams (24%). Over eight in 10 (81%) developers surveyed said they were accountable for any vulnerable code produced.
Developers motivated to upskill
‘Increased productivity and efficiency’, ‘curiosity’ and ‘avoiding problems caused by insecure code’ were identified as the leading intrinsic motivators to learn secure coding (20%, 14% and 11% respectively). Despite only 10% of respondents listing career advancement as a personal motivator, four in five (81%) managers were more likely to hire talent with secure coding skills.
More training is needed
91% of managers surveyed said they faced greater than average difficulty when implementing secure coding practices within their organisation, despite the overwhelming majority of respondents (97%) believing they were sufficiently trained. Perhaps, this is because almost nine in 10 (88%) developers surveyed said coding securely was challenging.
Madou added, “With OWASP’s Top 10 software vulnerabilities causing more security breaches over the past two decades than any others, now is the time for businesses to upskill developers to gain the knowledge and skills needed to stamp out insecure code and prevent issues from occurring in the first place. ”
“Code is at the heart of everyday interactions, and Secure Code Warrior is focused on championing security-skilled developers who can create amazing, safe software for our connected world .”
To gain early access to the report, ‘Shifting from reaction to prevention: The changing face of application security 2021’, register your interest at scw.buzz/earlyaccess
Methodology
Secure Code Warrior® commissioned Evans Data Corporation, the market intelligence leader within the IT industry, to conduct a global survey of developers and decision-makers actively engaged in software development. In August 2020, 400 respondents were surveyed across North America, India, the United Kingdom, Europe, Australia, New Zealand and South-East Asia.
About Secure Code Warrior
Secure Code Warrior is the developer-chosen solution for growing powerful secure coding skills. By making secure coding a positive and engaging experience for developers as they increase their software security skills, our human-led approach uncovers the secure developer inside every coder, helping development teams ship quality code faster.
Through inspiring a global community of security-conscious developers to embrace a preventative secure coding approach, our mission is to pioneer a people-first solution to security upskilling, stamping out poor coding patterns for good. Learn more at securecodewarrior.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323006113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom